Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totaling 243,112 shares, a growth of 1,971.5% from the November 30th total of 11,736 shares. Currently, 8.1% of the shares of the stock are short sold. Based on an average daily volume of 3,581,141 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 3,581,141 shares, the short-interest ratio is currently 0.1 days. Currently, 8.1% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Exicure in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Exicure Stock Up 2.8%

Shares of Exicure stock traded up $0.17 during trading hours on Wednesday, reaching $6.01. 43,749 shares of the company’s stock were exchanged, compared to its average volume of 225,077. Exicure has a 1 year low of $3.10 and a 1 year high of $18.43. The company has a market capitalization of $38.25 million, a P/E ratio of -1.62 and a beta of 4.08. The business has a fifty day moving average of $4.81 and a two-hundred day moving average of $5.69.

Exicure (NASDAQ:XCUR) last posted its quarterly earnings results on Friday, November 7th. The company reported ($0.39) earnings per share for the quarter.

Insider Buying and Selling at Exicure

In related news, major shareholder Sangsangin Investment & Securi sold 433,332 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $8.71, for a total transaction of $3,774,321.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 52.80% of the stock is currently owned by company insiders.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.